{'fraction_non_alphanumeric': 0.04601899196493791, 'fraction_numerical': 0.0723155588020453, 'mean_word_length': 4.555780933062881, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
COVID-19 and Obstructive Lung Disease: Are COPD and Asthma Risk Factors for Severe COVID-19? Evaluating the Data from the Largest Health System in New York State

RATIONALE: An analysis of data collected between March 1, 2020 through July 1, 2020 from the largest health system in New York sought to investigate the association between COVID-19 and obstructive lung disease including asthma and chronic obstructive pulmonary disease (COPD). Methods: A total of 21,865 patients were included in the analysis, 2,518 had obstructive lung disease and COVID-19. There were 1,370 [HA1] patients who had asthma and COVID-19, and 847 patients had COPD and COVID-19. There were 301 patients who had overlapping asthma and COPD diagnoses. There were 19,347 patients who had a diagnosis of COVID-19 without asthma or COPD. Logistic regression analysis of the data was performed. Results: Analysis of our data showed COPD patients with COVID-19 were more likely to be intubated as compared to the control group (OR 1.346 95% CI 1.061-1.707 p=0.0095). Additionally, there was no association between COPD and mortality in patients with COVID-19 (OR 0.845, 95% CI: 0.685-1.042 p=0.1436). There was no association between asthma and COVID-19 and intubation (OR 1.175 95% CI 0.936-1.475 p=0.2193). There was no statistical association between asthma and mortality in patients with COVID-19 (OR 0.849 95% CI 0.669-1.079 p=0.2455). However, patients with asthma were at a decreased risk of dying from COVID-19 compared to COPD patients with COVID-19 even after controlling for comorbid conditions (OR 0.718, 95% CI 0.526-0.979 p=0.0329). Patients presenting with asthma exacerbation or COPD exacerbation in the setting of COVID-19 infection were not at increased risk of death as compared to COPD or asthma patients with COVID-19 (Asthma exacerbation OR 1.042, 95% CI 0.62-1.73 p=0.8796), (COPD exacerbation OR 0.95 95% CI 0.67-1.36 p=0.762). Conclusion: Our finding with regards to intubation may be explained by an aggressive approach early on in the pandemic towards intubation especially in patients that may have been perceived as high-risk patients' due to underlying lung disease. Our data also showed no association between COPD and death in COVID-19 and asthma and mortality in COVID-19-meaning COPD and Asthma were not risk factors for death in our patient population. As to why asthma patients were at decreased odds of dying compared to COPD patients may be related to the different pathophysiological mechanisms of asthma as compared to COPD or a small protective effect of inhaled corticosteroids. Lastly, presenting with an asthma exacerbation or COPD exacerbation in the setting of COVID-19 infection did not increase your odds of mortality.